These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 16355501)

  • 1. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover.
    Nenonen A; Cheng S; Ivaska KK; Alatalo SL; Lehtimäki T; Schmidt-Gayk H; Uusi-Rasi K; Heinonen A; Kannus P; Sievänen H; Vuori I; Väänänen HK; Halleen JM
    J Bone Miner Res; 2005 Oct; 20(10):1804-12. PubMed ID: 16355501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
    Tähtelä R; Seppänen J; Laitinen K; Katajamäki A; Risteli J; Välimäki MJ
    Osteoporos Int; 2005 Sep; 16(9):1109-16. PubMed ID: 15605190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical performance of six different serum tartrate-resistant acid phosphatase assays for monitoring alendronate treatment.
    Fagerlund KM; Janckila AJ; Ylipahkala H; Tiitinen SL; Nenonen A; Cheng S; Uusi-Rasi K; Yam LT; Väänänen HK; Halleen JM
    Clin Lab; 2008; 54(9-10):347-54. PubMed ID: 19097492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-related changes of serum tartrate-resistant acid phosphatase 5b and the relationship with bone mineral density in Chinese women.
    Qin YJ; Zhang ZL; Zhang H; Hu WW; Liu YJ; Hu YQ; Li M; Gu JM; He JW
    Acta Pharmacol Sin; 2008 Dec; 29(12):1493-8. PubMed ID: 19026169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical markers of bone metabolism and prediction of fracture in elderly women.
    Gerdhem P; Ivaska KK; Alatalo SL; Halleen JM; Hellman J; Isaksson A; Pettersson K; Väänänen HK; Akesson K; Obrant KJ
    J Bone Miner Res; 2004 Mar; 19(3):386-93. PubMed ID: 15040826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
    Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
    J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model.
    Rissanen JP; Suominen MI; Peng Z; Halleen JM
    Calcif Tissue Int; 2008 Feb; 82(2):108-15. PubMed ID: 18084692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption.
    Hannon RA; Clowes JA; Eagleton AC; Al Hadari A; Eastell R; Blumsohn A
    Bone; 2004 Jan; 34(1):187-94. PubMed ID: 14751577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.
    Fink E; Cormier C; Steinmetz P; Kindermans C; Le Bouc Y; Souberbielle JC
    Osteoporos Int; 2000; 11(4):295-303. PubMed ID: 10928218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W; Muley T; Herb KP; Schmidt-Gayk H
    Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction.
    Yamada S; Inaba M; Kurajoh M; Shidara K; Imanishi Y; Ishimura E; Nishizawa Y
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):189-96. PubMed ID: 18221403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
    Choi HJ; Im JA; Kim SH
    Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density.
    Halleen JM; Ylipahkala H; Alatalo SL; Janckila AJ; Heikkinen JE; Suominen H; Cheng S; Väänänen HK
    Calcif Tissue Int; 2002 Jul; 71(1):20-5. PubMed ID: 12073156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRACP 5b and CTX as osteological markers of delayed fracture healing.
    Moghaddam A; Müller U; Roth HJ; Wentzensen A; Grützner PA; Zimmermann G
    Injury; 2011 Aug; 42(8):758-64. PubMed ID: 21168135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical utility of TRACP-5b to monitor anti-resorptive treatments of osteoporosis.
    Gossiel F; Ugur A; Peel NFA; Walsh JS; Eastell R
    Osteoporos Int; 2022 Jun; 33(6):1357-1363. PubMed ID: 35102444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.
    Yamada S; Tsuruya K; Yoshida H; Taniguchi M; Haruyama N; Tanaka S; Eriguchi M; Nakano T; Kitazono T
    Clin Endocrinol (Oxf); 2013 Jun; 78(6):844-51. PubMed ID: 23078546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
    Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A
    Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Sarioglu M; Tuzun C; Unlu Z; Tikiz C; Taneli F; Uyanik BS
    Rheumatol Int; 2006 Jan; 26(3):195-200. PubMed ID: 15580349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism.
    Lu KC; Tseng CF; Wu CC; Yeung LK; Chen JS; Chao TY; Janckila AJ; Yam LT; Chu P
    Blood Purif; 2006; 24(5-6):423-30. PubMed ID: 16888370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.